Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 13,019

Document Document Title
WO/2018/011160A1
The present invention relates to compounds of the formula (I) or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis...  
WO/2018/011681A1
Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, a...  
WO/2018/011527A1
The present invention relates to reagents for reversibly protecting biological molecules. In particular, it relates to compounds derived from azaisotoic anhydride and the uses of same for protecting biological molecules, particularly enz...  
WO/2018/013948A1
Mitochondria-targeting potassium sensors and method(s) for making such sensors. The sensor shows a response to potassium and displays a 130-fold dynamic range of fluorescence intensity and high brightness. The sensors response to potassi...  
WO/2018/008920A1
Provided is a pharmaceutical composition for preventing and treating tumors, the pharmaceutical composition including an imidazooxazole derivative compound, a solvate, a stereoisomer, or a pharmaceutically acceptable salt thereof as an a...  
WO/2018/009417A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.  
WO/2018/005328A1
This invention relates to deuterated forms of bictegravir, and pharmaceutically acceptable salts thereof. In one aspect, the invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein each of Y1, ...  
WO/2018/005881A1
Provided herein are compounds of formula (IA) and (III) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in t...  
WO/2018/005192A1
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2018/005591A1
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of ...  
WO/2018/002219A1
Fused aromatic bicyclic substituted 5-(2-amino-4-pyrimidinyl)- cyanoindoline derivatives (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful...  
WO/2017/221869A1
Provided is a method for producing a substituted polycyclic pyridone derivative. A method for producing a compound represented by formula (II), which is characterized in that a compound represented by formula (I) is reacted with a compou...  
WO/2017/219808A1
Provided are a compound as shown in formula (I) usable as a hepatitis C virus inhibitor, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, usable to treat hepatitis C virus (HCV) infections or hepa...  
WO/2017/215588A1
Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (1) or a pharmaceutically acceptable salt thereof.  
WO/2017/215600A1
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...  
WO/2017/218843A1
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof. (Formu...  
WO/2017/218960A1
Described herein are compounds, including pharmaceutically acceptable salts thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, prevent or diagno...  
WO/2017/212425A1
The invention is directed to substituted piperidine derivatives. Specifically, the invention is directed to compounds according to Formula IIII: wherein A, B, X, Y, L1, L2, L3, R1, R2, R3, R4, R5, R6, R9, z2, z4, z5, and z6 are as define...  
WO/2017/211759A1
The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.  
WO/2017/211760A1
The present invention relates to novel antibacterial compounds (1) as defined below, pharmaceutical compositions containing them and their use as antimicrobials. A compound of formula (1): A-L1-Y-L2-R-B, wherein A is a cyclic group havin...  
WO/2017/213210A1
The present invention relates to a compound potentially useful as a prophylactic or therapeutic drug for cancer.  
WO/2017/214423A3
In one aspect, the present disclosure provides analogs of thailanstatin of the formula wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed here...  
WO/2017/211303A1
Provided are certain pyrazine derivatives (I) as SHP2 inhibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused heterocyclic derivatives useful as...  
WO/2017/207540A1
The present invention relates to novel anthracycline derivatives comprising two oxazolidine cycles and the preparation of said anthracycline derivatives. Furthermore, antibody-drug conjugates (ADCs) comprising the novel anthracycline der...  
WO/2017/208105A1
The present invention provides novel crystalline form A of dolutegravir sodium with characteristic diffraction peaks at 6.3, 7.8, 9.3, 11.4, 12.4, 13.5, 12.7, 15.1, 15.8, 18.3, 19.0, 19.6, 20.7, 22.8, 23.1, 24.3 and 25.8 ± 0.2 degree tw...  
WO/2017/209155A1
Provided are: a novel sulfonamide compound having ribonucleotide reductase inhibitory activity or a salt thereof; and a pharmaceutical composition which contains this sulfonamide compound or a salt thereof as an active ingredient. A comp...  
WO/2017/210545A1
Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided...  
WO/2017/202390A1
Provided in the present invention is a heterocyclic compound serving as an FGFR4 (fibroblast growth factor receptor 4) inhibitor. Specifically, provided in the present invention is the compound shown in formula (I), including isomers (en...  
WO/2017/201846A1
A preparation method of an antibacterial oxazolidinone medicine and an intermediate thereof. The preparation method avoids using explosive azide compounds and allergenic and genotoxic chlorides, and avoids a column chromatography purific...  
WO/2017/202748A1
Compounds of the formula (I) in which R1 and R2 have the meanings indicated in Claim 1,are inhibitors of ATR, and can be employed for the treatment of diseases such as cancer.  
WO/2017/198102A1
Provided are a substituted macrocyclic quinoxaline compound and a pharmaceutical composition and use thereof, wherein the macrocyclic quinoxaline compound is the compound as shown in formula (I), or a polymorph, a pharmaceutically accept...  
WO/2017/198341A1
The present invention relates to macrocyclic indole derivatives of general formula (I) : (I), in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparin...  
WO/2017/199265A1
The present disclosure relates to compounds of Formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms thereof and pharmaceutical com...  
WO/2017/200863A1
The present invention provides N-[3-[2-Amino-5-(1,1-difluoroethyl) -4,4a,5,7-tetrahydrofuro[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-p henyl]-5- (trifluoromethyl)pyridine-2-carboxamide, i.e. the compound of Formula I: [Formula should be inserte...  
WO/2017/196261A1
The present disclosure described provides novel dual inhibition compounds that specifically target the JAK-STAT and HDAC pathways, two distinct cellular pathways that are useful in the treatment of various diseases and disorders. In cert...  
WO/2017/196210A1
The invention relates to the chemistry of organic compounds, to pharmacology and to medicine, and pertains to the prevention and treatment of human and animal diseases associated with metabolic disorders of bone tissues and/or cartilage ...  
WO/2017/190345A1
Provided is the design, synthesis and applications of molecular fluorophores for bioimaging in the short wavelength infrared window (1000-1700 nm). The molecular fluorophores compound comprise structures with electron accepting aromatic ...  
WO/2017/191304A1
The present invention relates to new compounds of general formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially α2δ-1 subunit of voltage-gated calcium channels ...  
WO/2017/192930A1
The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and comp...  
WO/2017/192961A1
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...  
WO/2017/189661A1
The present invention comprises compounds of Formula (I) wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein...  
WO/2017/186148A1
Disclosed is a compound of Formula (Ⅰ) or a pharmaceutically acceptable salt thereof, wherein the variables are described herein. Also disclosed is a process for the preparation of compounds, their pharmaceutical compositions comprisin...  
WO/2017/181947A1
The present invention provides a substituted diamine carbamate, and a pharmaceutical composition and application thereof. The diamine carbamate is a compound represented by formula (I), or a crystalline form, pharmaceutically acceptable ...  
WO/2017/179002A1
The invention relates to antibacterial compounds of formula (I), wherein U1 represents N or CH, U2 represents N or CH, U3 represents N or CH, it being understood that at most two of U1, U2, U3 can represent N at the same time; V1 represe...  
WO/2017/177828A1
The present invention relates to a novel oxazolidinone-fluoroquinolone derivative and uses, and relates to the field of chemical drugs. The present invention also relates to a compound represented by formula (I), a pharmaceutically accep...  
WO/2017/177837A1
The present invention relates to a heterocyclic-substituted pyridinopyrimidinone derivative, and the use thereof as a therapeutically effective cyclin-dependent kinase (CDK) inhibitor. In particular, the present invention relates to the ...  
WO/2017/176981A1
Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorde...  
WO/2017/177004A8
Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation ...  
WO/2017/177004A1
Compunds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation o...  
WO/2017/175091A1
This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17 -tetrahydro-2H-8,4-(metheno)pyrazolo[4,3- h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile(lorlat inib) maleate. The inv...  

Matches 1 - 50 out of 13,019